` IPH (Innate Pharma SA) vs DAX Index Comparison - Alpha Spread

IPH
vs
DAX Index

Over the past 12 months, IPH has underperformed DAX Index, delivering a return of -24% compared to the DAX Index's 30% growth.

Stocks Performance
IPH vs DAX Index

Loading
IPH
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
IPH vs DAX Index

Loading
IPH
DAX Index
Difference
www.alphaspread.com

Performance By Year
IPH vs DAX Index

Loading
IPH
DAX Index
Add Stock

Competitors Performance
Innate Pharma SA vs Peers

DAX Index
IPH
ABBV
AMGN
GILD
VRTX
Add Stock

Innate Pharma SA
Glance View

Market Cap
180.6m EUR
Industry
Biotechnology

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

IPH Intrinsic Value
4.6 EUR
Undervaluation 57%
Intrinsic Value
Price
Back to Top